← Search & browse all drugs

cetrimonium

R02AA17

Forms & Strengths

Throat lozenges 0.25% w/v cetrimonium bromide
Mouthwash solution 0.025% w/v
Spray for oral mucosa 0.1% w/v
Gel for gingival use 0.2% w/v

Adult Dosing

Lozenge: 1 lozenge every 2–3 h, max 6 lozenges/day
Mouthwash: 15 mL, gargle 30 s, 3–4 times daily
Spray: 2–3 sprays to affected area, up to 4 times/day
Do not exceed 0.5 g cetrimonium total daily

Pediatric Dosing

Age ≥ 2 y: lozenge ½ dose (½ lozenge q4–6 h, max 3/day) or diluted mouthwash (½ strength)
Age < 2 y: not recommended
Spray: 1–2 sprays to mucosa, max 3 times/day for children 6‑12 y
Monitor for local irritation

Indications

Acute sore throat (pharyngitis) of viral or mild bacterial origin
Oral mucosal infections (candidiasis, ulcerations)
Post‑operative oral hygiene
Minor dental/gingival infections

Mechanism of Action

Quaternary ammonium surfactant disrupting microbial cell membranes
Causes leakage of intracellular contents → rapid bactericidal effect
Broad‑spectrum activity against Gram‑positive, some Gram‑negative bacteria and enveloped viruses
Reduces plaque formation by inhibiting bacterial adhesion

Contraindications

Known hypersensitivity to cetrimonium or other quaternary ammonium compounds
Severe mucosal ulceration or erosions
Children <2 years (lack of safety data)
Caution in pregnancy/breast‑feeding – use only if benefit outweighs risk

Adverse Reactions

Transient oral burning or stinging sensation
Taste alteration (metallic/bitter)
Local allergic contact dermatitis or erythema
Rare systemic effects: nausea, dizziness if excessive use

Drug Interactions

May inactivate anionic drugs (e.g., chlorhexidine) by ionic binding
Concurrent use with other topical antiseptics can increase mucosal irritation
Potential additive irritation when combined with corticosteroid lozenges
No significant systemic drug‑drug interactions known

Curated Content: Needs Vetting Before Put to Clinical Use